Delivery Order SPE2DB22D2005-SPE2DB25FJRP2
- Not listed
- The Defense Logistics Agency awarded a $16,403.16 delivery order to AmerisourceBergen Drug Corp on August 28, 2025, for the supply of Zepbound 7.5 mg/0.5 ml pen injectors. This firm fixed price, non-competitive delivery order is set to be completed by August 29, 2025, with performance executed at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. The contract represents a child order under AmerisourceBergen's broader Indefinite Delivery Contract with DLA Troop Support...
- The Defense Logistics Agency awarded a $5,103.02 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Zepbound 10 mg/0.5 mL pen injections on September 22, 2025, with completion scheduled for September 23, 2025. This award represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999 through December 2026. The contract was competitively awarded with no set-aside designation, and...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Zepbound 2.5 mg/0.5 mL pen injections (0.5 mL units) with a ceiling value of $1,659.37. This firm fixed-price delivery order, which is set to be completed by August 15, 2025, will be fulfilled from AmerisourceBergen's Conshohocken, Pennsylvania facility. The award represents a non-competitive delivery order issued under AmerisourceBergen's existing indefinite delivery...
- The Defense Logistics Agency awarded a $7,509.40 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Zepbound 7.5 mg/0.5 ml pen injections on August 19, 2025, with ultimate completion scheduled for August 20, 2025. This competitive award, placed under no set-aside designation, represents a child delivery order issued against AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a comprehensive pharmaceutical prime vendor agreement...
- The Defense Logistics Agency awarded a $18,566.54 delivery order to AmerisourceBergen Drug Corp for the supply of Zepbound 5 mg/0.5 ml pen injectors on August 8, 2025, with an ultimate completion date of August 11, 2025. This is a firm fixed price contract with no set-aside designation, competitively awarded under open competition. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is a child contract issued under...
- The Defense Logistics Agency awarded a $28,634.71 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of Zepbound 5 mg/0.5 mL pen injectors on August 11, 2025. This non-set-aside contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999, which runs through December 2026. The performance location is the company's corporate office in Conshohocken, Pennsylvania, with...
- The Defense Logistics Agency awarded a $39,896.58 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of Zepbound 10 mg/0.5 mL pen injectors on September 3, 2025, with an ultimate completion date of September 4, 2025. This non-set-aside contract is performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's broader Indefinite Delivery Contract (IDC) with DLA Troop Support Medical,...
- The Defense Logistics Agency awarded a delivery order valued at $14,661.49 to AmerisourceBergen Drug Corp for the supply of Zepbound 2.5 mg/0.5 ml pen injectors on July 23, 2025. This firm fixed-price delivery order is non-competitive and will be performed at the contractor's facility in Conshohocken, Pennsylvania, with completion scheduled for July 24, 2025. The award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical...
- The Defense Logistics Agency awarded a delivery order valued at $39,096.11 to AmerisourceBergen Drug Corp for the supply of Zepbound 5 mg/0.5 ml pen injectors on August 26, 2025. This firm fixed-price, competitively awarded contract (no set-aside) specifies performance at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of August 27, 2025. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a $1,143.87 firm fixed-price delivery order on July 22, 2025, for Zepbound 15 mg/0.5 ml pen injections. This is a competitively awarded, non-set-aside contract with performance at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, and an ultimate completion date of July 23, 2025. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA...
- SPE2DB22D2005Indefinite Delivery Contract
- SPE2DB22D2005-SPE2DB25FJRP2Delivery Order
The Defense Logistics Agency awarded a $10,312.67 firm fixed-price delivery order to AmerisourceBergen Drug Corp for supply of Zepbound 15 mg/0.5 ml pen injectors on August 13, 2025, with an ultimate completion date of August 14, 2025. The contract, classified as a non-competitive delivery order, will be performed at the awardee's corporate office location in Conshohocken, Pennsylvania. This award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), which is valued at $999,999,999 and extends through December 2026, serving as a comprehensive global pharmaceutical support vehicle for military healthcare programs. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, supplies a broad range of medications and medical commodities to federal healthcare systems, including the Department of Defense and Veterans Affairs. The Zepbound delivery order supports military medical supply chain needs, providing this GLP-1 receptor agonist medication used in diabetes and weight management treatment protocols. As a consistently competitive award winner through the DLA's pharmaceutical procurement processes, AmerisourceBergen demonstrates the capability to fulfill diverse federal medical supply requirements across multiple therapeutic domains, from specialty medications to vaccines and medical devices.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $10.3k | 8/13/25 |